Eva Loranc

482 total citations
6 papers, 330 citations indexed

About

Eva Loranc is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Eva Loranc has authored 6 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 1 paper in Cellular and Molecular Neuroscience and 1 paper in Cardiology and Cardiovascular Medicine. Recurrent topics in Eva Loranc's work include Genomics, phytochemicals, and oxidative stress (3 papers), Histone Deacetylase Inhibitors Research (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). Eva Loranc is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (3 papers), Histone Deacetylase Inhibitors Research (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). Eva Loranc collaborates with scholars based in United States, Brazil and Australia. Eva Loranc's co-authors include Alexander J.R. Bishop, Aparna Gorthi, V. Pragathi Masamsetti, Yidong Chen, Xavier Bernard, July Carolina Romero, Lin Cao, Elizabeth R. Lawlor, Kimberly Stegmaier and Jeffrey A. Toretsky and has published in prestigious journals such as Nature, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Eva Loranc

6 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Loranc United States	6	249	77	53	41	28	6	330
Zhanzhan Feng China	14	273 1.1×	102 1.3×	38 0.7×	35 0.9×	50 1.8×	19	395
Man Li China	10	260 1.0×	81 1.1×	40 0.8×	52 1.3×	50 1.8×	23	349
Adam Gastonguay United States	11	209 0.8×	47 0.6×	51 1.0×	48 1.2×	52 1.9×	11	346
Quyen Thu Bui South Korea	7	190 0.8×	93 1.2×	40 0.8×	60 1.5×	37 1.3×	11	279
J.M. Holzbeierlein United States	7	272 1.1×	77 1.0×	109 2.1×	66 1.6×	24 0.9×	8	392
J-H Luo United States	6	233 0.9×	46 0.6×	45 0.8×	80 2.0×	41 1.5×	7	349
Vanessa Nancy-Portebois France	5	169 0.7×	48 0.6×	32 0.6×	51 1.2×	50 1.8×	6	344
Derek J. Hoelz United States	9	278 1.1×	93 1.2×	24 0.5×	60 1.5×	45 1.6×	15	387
Felix Agbo United States	8	232 0.9×	192 2.5×	45 0.8×	23 0.6×	38 1.4×	14	356
Sandra Bien-Möller Germany	12	235 0.9×	108 1.4×	36 0.7×	87 2.1×	52 1.9×	19	403

Countries citing papers authored by Eva Loranc

Since Specialization

Citations

This map shows the geographic impact of Eva Loranc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Loranc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Loranc more than expected).

Fields of papers citing papers by Eva Loranc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Loranc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Loranc. The network helps show where Eva Loranc may publish in the future.

Co-authorship network of co-authors of Eva Loranc

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Loranc. A scholar is included among the top collaborators of Eva Loranc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Loranc. Eva Loranc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Jaiswal, Aruna S., Arijit Dutta, Gayathri Srinivasan, et al.. (2023). TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells. Nucleic Acids Research. 51(22). 12224–12241. 10 indexed citations

2.

Zanotto‐Filho, Alfeu, Subapriya Rajamanickam, Eva Loranc, et al.. (2018). Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Letters. 425. 101–115. 26 indexed citations

3.

Gorthi, Aparna, July Carolina Romero, Eva Loranc, et al.. (2018). EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 555(7696). 387–391. 209 indexed citations

4.

Zanotto‐Filho, Alfeu, V. Pragathi Masamsetti, Eva Loranc, et al.. (2016). Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Molecular Cancer Therapeutics. 15(12). 3000–3014. 55 indexed citations

5.

Zanotto‐Filho, Alfeu, Dashnamoorthy Ravi, Eva Loranc, et al.. (2016). Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS ONE. 11(4). e0153970–e0153970. 6 indexed citations

6.

Loranc, Eva, et al.. (2009). Bimane Fluorescence Scanning Suggests Secondary Structure near the S3-S4 Linker of BK Channels. Journal of Biological Chemistry. 284(16). 10684–10693. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact